Le Lézard
Classified in: Health
Subject: CCA

Ionis Pharmaceuticals to present at upcoming investor conferences


CARLSBAD, Calif., Nov. 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

ABOUT IONIS PHARMACEUTICALS, INC.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

SOURCE Ionis Pharmaceuticals, Inc.


These press releases may also interest you

at 09:10
Pharmatech Associates today announced the promotion of Mustafa Abdallah to the position of vice president, regulatory compliance, from his previous role as director. Mr. Abdallah works with a broad array of life science organizations, drug and device...

at 09:09
Marking another milestone for the world's fastest growing fitness boot camp franchise, Fit Body Boot Camp has landed on Entrepreneur Magazine's 2020 Franchise 500® list, the world's first, best and most comprehensive franchise ranking. Fit Body Boot...

at 09:05
Pharmatech Associates today announced the addition of Maureen Merrifield, Ph.D., as vice president, clinical and regulatory affairs. She is responsible for oversight and management of all clinical and regulatory strategy and support activities...

at 09:05
Revive Therapeutics Ltd. ("Revive" and the "Company") , a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company's announcement on January...

at 09:00
Medicare Advantage Open Enrollment Period (MAOEP) is from January 1 ? March 31. It's a time when seniors can potentially save money and gain benefits. Unfortunately, many seniors will do neither. But why is the Open Enrollment Period ignored by...

at 09:00
T2 Tech Group, an industry leader in delivering management consulting and advisory services that align business strategy with technology solutions to deliver results across a diverse client base, has named James "Jim" Rockenbach as its new chief...



News published on 12 november 2019 at 07:05 and distributed by: